American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

SANGAMO THERAPEUTICS, INC (SGMO)

$0.07 -57.53% OTC: SGMO · 15-min delayed

RICHMOND, California
Public · OTC: SGMO

Visit website Follow

$39.6MRevenue · FY2025

-$122.9MNet income

SGMOOTC

About SANGAMO THERAPEUTICS, INC

SANGAMO THERAPEUTICS INC

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · OTC: SGMO
Headquarters: RICHMOND, California
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: SGMO OTC
SEC CIK: 1001233
EIN: 680359556
SIC: 2836 Biological Products, (No Diagnostic Substances)

Embed this company’s badge

Show Sangamo Therapeutics, Inc’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/sangamo-therapeutics-inc/"><img src="https://americancompanies.com/badge/sangamo-therapeutics-inc.svg" alt="Sangamo Therapeutics, Inc — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow SANGAMO THERAPEUTICS, INC and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $39.6M
Net income: -$122.9M
Total assets: $59.7M
Operating margin: -306.5%
Net margin: -310.8%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $39.6M
Operating expenses: $160.8M
Operating income: -$121.2M
Income tax: -$568.0K
Net income: -$122.9M
EPS (basic): $-0.44
EPS (diluted): $-0.44

Balance sheet

Total assets: $59.7M
Current assets: $35.8M
Total liabilities: $74.0M
Current liabilities: $42.5M
Shareholders’ equity: -$14.3M

Cash flow

Operating cash flow: -$97.2M
Investing cash flow: -$102.0K
Financing cash flow: $70.7M
Net cash flow: -$22.5M

Statements via Polygon.io (SEC filings)

OTC: SGMO

$0.07 -57.53%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.07 $0.74

52-week range

EPS (diluted): $-0.44
Open: —
Day range: –
Prev close: —
Volume: —

Sangamo Therapeutics, Inc (SGMO) Stock Price

Reported a net loss of $122.9M in FY2025.
Revenue declined 64% from FY2021 to FY2025.
Trading 91% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review SANGAMO THERAPEUTICS, INC.

Write a review

Newsroom

News about SANGAMO THERAPEUTICS, INC

Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy Benzinga · 2026-06-12 · negative Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends GlobeNewswire Inc. · 2026-01-22 · positive US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' Benzinga · 2025-03-18 · negative Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight GlobeNewswire Inc. · 2025-02-21 · positive Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI GlobeNewswire Inc. · 2025-01-02 · positive Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact Benzinga · 2024-12-31 · negative

News & sentiment via Polygon.io

FAQ

Sangamo Therapeutics, Inc: frequently asked questions

Is Sangamo Therapeutics, Inc an American company?

Sangamo Therapeutics, Inc is a US-based company headquartered in Richmond, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Sangamo Therapeutics, Inc headquartered?

Sangamo Therapeutics, Inc is headquartered in Richmond, California, United States.

Is Sangamo Therapeutics, Inc publicly traded?

Yes — Sangamo Therapeutics, Inc is a publicly traded company. Its stock trades under the ticker symbol SGMO on the OTC.

What does Sangamo Therapeutics, Inc do?

Sangamo Therapeutics, Inc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore